Form 4: Amicus Therapeutics CFO Simon Harford Reports Stock Transactions and Option Grants

Amicus Therapeutics' Chief Financial Officer, Simon N.R. Harford, reported the acquisition of restricted stock units and stock options, along with the disposal of shares to cover tax obligations.

Summary

• Simon N.R. Harford, the Chief Financial Officer of Amicus Therapeutics, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On January 2, 2025, Mr. Harford disposed of 7,482 shares of common stock at a price of $9.31 per share.
• On January 3, 2025, he acquired 83,073 restricted stock units (RSUs) at no cost, which will vest in four equal annual installments starting January 3, 2026.
• Also on January 3, 2025, Mr. Harford was granted 150,517 stock options with an exercise price of $9.41, vesting over four years.

Sentiment

Score: 6

Explanation: The document reflects standard insider transactions and compensation practices. There are no significant positive or negative surprises, resulting in a neutral to slightly positive sentiment due to the long-term incentive alignment.

Positives

• The grant of 83,073 restricted stock units and 150,517 stock options to the CFO indicates a long-term incentive and alignment with the company's future performance.
• The vesting schedule of the RSUs and options encourages continued service and commitment from the CFO.

Negatives

• The sale of 7,482 shares by the CFO, while likely for tax obligations, could be perceived negatively by some investors.

Risks

• The vesting of the RSUs and options is contingent on continued employment, which could be a risk if the CFO were to leave the company.
• The market price of the stock could fluctuate, affecting the value of the options and RSUs.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the vesting schedules of the RSUs and options suggest a long-term focus.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency into the holdings and incentives of key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in the biotechnology and pharmaceutical industries.
• Vesting schedules are typically structured to align executive interests with long-term company performance, similar to other companies in the sector such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The four-year vesting period for both RSUs and options is a common practice in the industry.

Stakeholder Impact

• Shareholders may view the stock transactions as a routine part of executive compensation.
• Employees may see the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Insider Trading, Amicus Therapeutics, Simon Harford, CFO